Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Payables (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Payables for 7 consecutive years, with $17.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 14.03% to $17.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.6 million through Dec 2025, up 14.03% year-over-year, with the annual reading at $17.6 million for FY2025, 14.03% up from the prior year.
  • Payables hit $17.6 million in Q4 2025 for IDEAYA Biosciences, down from $18.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $18.4 million in Q3 2025 to a low of $1.3 million in Q1 2021.
  • Historically, Payables has averaged $8.3 million across 5 years, with a median of $5.5 million in 2023.
  • Biggest YoY gain for Payables was 180.3% in 2025; the steepest drop was 8.71% in 2025.
  • Year by year, Payables stood at $2.1 million in 2021, then surged by 103.81% to $4.3 million in 2022, then surged by 54.16% to $6.6 million in 2023, then skyrocketed by 133.72% to $15.4 million in 2024, then grew by 14.03% to $17.6 million in 2025.
  • Business Quant data shows Payables for IDYA at $17.6 million in Q4 2025, $18.4 million in Q3 2025, and $17.3 million in Q2 2025.